Thermo Fisher Scientific Inc. (TMO)
NYSE: TMO · Real-Time Price · USD
422.62
-0.93 (-0.22%)
May 5, 2025, 4:00 PM EDT - Market closed
Thermo Fisher Revenue
Thermo Fisher had revenue of $10.36B in the quarter ending March 29, 2025, with 0.18% growth. This brings the company's revenue in the last twelve months to $42.90B, up 0.96% year-over-year. In the year 2024, Thermo Fisher had annual revenue of $42.88B with 0.05% growth.
Revenue (ttm)
$42.90B
Revenue Growth
+0.96%
P/S Ratio
3.75
Revenue / Employee
$343,184
Employees
125,000
Market Cap
159.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 42.88B | 22.00M | 0.05% |
| Dec 31, 2023 | 42.86B | -2.06B | -4.58% |
| Dec 31, 2022 | 44.92B | 5.70B | 14.55% |
| Dec 31, 2021 | 39.21B | 6.99B | 21.71% |
| Dec 31, 2020 | 32.22B | 6.68B | 26.14% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Abbott Laboratories | 42.34B |
TMO News
- 5 days ago - 3 Of The Cheapest High-Quality Stocks Money Can Buy - Seeking Alpha
- 6 days ago - Baron Health Care Fund Q1 2025 Top Net Purchases And Sales - Seeking Alpha
- 7 days ago - Thermo Fisher Scientific Leverages Integrated Solutions to Accelerate the Development of Biologic Therapeutics - Business Wire
- 11 days ago - Thermo Fisher Doubles Down On US Manufacturing In $2B Expansion Plan - Benzinga
- 11 days ago - Thermo Fisher Scientific: Tariff And Policy Impacts Look Priced In - Seeking Alpha
- 11 days ago - Thermo Fisher Scientific Invests to Enhance U.S. Innovation and Support Customers' Manufacturing - Business Wire
- 12 days ago - Thermo Fisher Scientific Q1 Earnings Surpass Estimates, CEO Touts 'Strong Performance' Despite Economic Uncertainty - Benzinga
- 12 days ago - Thermo Fisher Tops Q1 Estimates in 'Uncertain Macroeconomic Environment' - Investopedia